Epilepsy Research


Expertise:

Our research program offers clinical trials and innovative research for patients with medically refractory epilepsies.

  • EpiNet

     Principal Investigator:
    Diep Bui, MD

     

    https://clinicaltrials.gov/study/NCT01662453?cond=SUDEP&rank=3

    Type of Study:
    Registry/ Observational

    Summary
    This study aims to develop a North American registry for SUDEP cases; requesting family members of epilepsy patients who died suddenly of unclear causes (SUDEP) to contact the study team. The family members who decide to participate in the study will be asked to complete a brief telephone interview about their loved one’s epilepsy and seizure history and the circumstances of his or her death. If the death has occurred within the past 24 hours, and the family is willing to consider donating tissue to the study, the subject will be transferred to the Autism Tissue Program, and the remainder of the phone interview will be conducted at a later time. One of the main objectives of this study is to investigate the role of various risk factors in the development of sudden unexplained death in patients with epilepsy, with a particular focus on the role of antiepileptic medications. In addition, we want to elucidate the pathophysiologic mechanisms leading to SUDEP

    Link to Sponsor’s Website:
    https://www.epinet.co.nz/current-studies/

    Study Coordinator:
    Anthony Torres
    Office: 210-450-8455
    Email: torresa23@uthscsa.edu

  • Retrospect EMU Study

     Principal Investigator:
    Charles Szabo, MD

     

    Type of Study:
    Registry/ Observational

    Summary
    This study aims to retrospectively compare cases of SUDEP with matched control subjects cared for by the same epilepsy center to identify risk factors and potential biomarkers associated with SUDEP.

    Study Coordinator:
    Anthony Torres
    Office: 210-450-8455
    Email: torresa23@uthscsa.edu

     

  • Epitel (REMI)

     Principal Investigator:
    Kameel Karkar, MD

     

    https://clinicaltrials.gov/study/NCT06027749

    Type of Study:
    Interventional

    Summary
    The goal of this clinical trial is to test Epitel’s™ Remote EEG Monitoring System’s (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 – 28 days) in patients presenting with questionable seizure characterization. The main questions it aims to answer are: Can more seizure events be recorded in fourteen (14) days than can be recorded in three (3) days? Do treating clinicians find clinical value in extended fourteen (14) – twenty-eight (28) days of EEG? Participants will wear a portable EEG device (REMI) for fourteen (14) to twenty-eight (28) days in their home/community setting

    The purpose of this study is to demonstrate that the REMI system is able to record EEG data that clinicians can use to identify ictal events over extended periods, and that extended clinical EEG data is valuable in the diagnosis and treatment of seizure related symptoms

    Link to Sponsor’s Website:
    https://www.epitel.com/about-epitel

    Study Coordinator:
    Anthony Torres
    Office: 210-450-8455
    Email: torresa23@uthscsa.edu

     

  • XPF-010-301 (X-TOLE2)

     Principal Investigator:
    Charles Szabo, MD

     

    https://clinicaltrials.gov/study/NCT05614063

    Type of Study:
    Interventional/Randomized Control

    Summary:
    The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures

    Link to Sponsor’s Website:
    https://www.xenon-pharma.com/about/

    Study Coordinator:
    Anthony Torres
    Office: 210-450-8455
    Email: torresa23@uthscsa.edu

     

  • XPF-010-303 (X-ACKT)

     Principal Investigator:
    Charles Szabo, MD

     

    https://clinicaltrials.gov/study/NCT05667142

    Type of Study:
    Interventional/Randomized Control

    Summary:
    This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS)

    Link to Sponsor’s Website:
    https://www.xenon-pharma.com/about/

    Study Coordinator:
    Anthony Torres
    Office: 210-450-8455
    Email: torresa23@uthscsa.edu

     

  • EPICOM

     Principal Investigator:
    Linda Leary, MD

     

    https://clinicaltrials.gov/study/NCT05864846

    Type of Study:
    Interventional/Open Label

    Summary:
    The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.

     

    Study Coordinator:
    Anthony Torres
    Office: 210-450-8455
    Email: torresa23@uthscsa.edu

     

  • BHV7000-302 (RISE 2)

     Principal Investigator:
    Octavian Lie, MD

     

    https://clinicaltrials.gov/study/NCT06132893

    Type of Study:
    Interventional/Randomized Control

    Summary:
    The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy

    Link to Sponsor’s Website:
    https://www.biohavenclinicaltrials.com/find-a-trial/?searchKeyword=focal%20epilepsy

    Study Coordinator:
    Anthony Torres
    Office: 210-450-8455
    Email: torresa23@uthscsa.edu